It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Bridging the gap between scientific innovation and patient impact, we deliver high-quality, clinically relevant in vivo data that drives faster, smarter decisions through tailored study designs, advanced technologies, and close collaboration across disciplines.
Sygnature Discovery supports projects at all drug discovery phases by delivering high-quality in vivo pharmacology data that drive confident decision making for our customers.
Our team of >60 in vivo scientist has deep expertise with a critical mass of projects and a proven track record in delivering validated models and impactful results across key therapeutic areas.
Our in vivo platform offers a full spectrum of solutions, including pharmacokinetics, target engagement and biomarkers, disease-relevant translational models, and exploratory toxicology. Continuous investment in advanced technologies enhance data translatability, improves project outcomes and maximize clinical relevance.
Each study is executed on time, with high quality and in full alignment with the highest standard of animal welfare.
Our in vivo Pharmacology Solutions
We offer extensive in vivo pharmacology capabilities and disease expertise across key therapeutic domains.
CNS/ Pain Models
We bring unique depth in central nervous system diseases, including psychiatric disorders a particularly complex area in drug development.
Our cutting-edge models address the complexities of metabolic disease. With decades of experience, we support discovery in obesity, diabetes, kidney disease and more.
We provide access to a wide range of ex vivo platforms for gene, protein, and cytokine analysis, including whole-cell and immune cell profiling via flow cytometry.
Decades of experience in applying in vivo models to drug discovery.
Integrated Science & Technology
Seamless integration of disciplines accelerates decision-making.
Tailored Collaboration
Flexible partnerships built around your goals and timelines.
Commitment to Excellence & Welfare
Studies conducted to the highest standards or scientific rigor and animal care.
High Quality Standards, Flexibility and Versatility Approach
Our in vivo research is led by highly trained scientists with deep expertise in preclinical models and animal welfare. We uphold the 3 Rs Replacement, Refinement, and Reduction – in every study, ensuring ethical and responsible research practices.
We apply a global quality aproach, embedded continuous learning and performance measurement to deliver on our promise of excellence.
Why Choose Sygnature Discovery for in vivo Pharmacology Support?
Our in vivo teams in the UK and Canada collaborate closely with Sygnature experts in in vitro pharmacology, DMPK, chemistry, and protein sciences. This co located, multidisciplinary approach broadens our capabilities, streamlines delivery, and enables fully integrated drug discovery solutions.
We support a wide range of modalities, including small molecules, biologic, oligonucleotides, and cell and gene therapies. Our state of-the-art facilities enable flexible study designs with short lead times. Our adaptable business models from standalone-fee-for service to full-time equivalent (FTE) arrangement align with your specific needs.
Meet our Team
Get to know the team powering our in vivo solutions. They bridge the gap between innovation and patient impact with tailored studies and advanced technologies.
Focusing on the craving phase of addiction, this article examines how behavioral pharmacology models capture cue‑driven drug seeking and relapse vulnerability.
Focusing on the withdrawal phase of addiction, this article examines how behavioral pharmacology models assess drug dependence and therapeutic intervention in preclinical studies.
Focusing on the intoxication phase of addiction, this article examines how behavioral pharmacology models capture reward, reinforcement and binge‑like drug use in preclinical studies.
Drug addiction remains one of the most persistent and complex public health challenges worldwide. Despite advances in prevention and treatment, drug‑related harm and mortality continue to rise, underscoring the need for deeper biological understanding and more predictive models to support the development of new therapies.
Discover precise insights into brain neurochemistry with Sygnature Discovery’s in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Technical Notes
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
